NasdaqCM:AEMD

Stock Analysis Report

Executive Summary

Aethlon Medical, Inc., a medical technology company, focuses on addressing unmet needs in health and biodefense worldwide.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has Aethlon Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AEMD's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-5.1%

AEMD

3.7%

US Medical Equipment

2.4%

US Market


1 Year Return

-89.6%

AEMD

-1.6%

US Medical Equipment

-10.0%

US Market

Return vs Industry: AEMD underperformed the US Medical Equipment industry which returned -5.2% over the past year.

Return vs Market: AEMD underperformed the US Market which returned -13.3% over the past year.


Shareholder returns

AEMDIndustryMarket
7 Day-5.1%3.7%2.4%
30 Day-52.6%-5.6%-11.0%
90 Day4.0%-14.5%-19.4%
1 Year-89.6%-89.6%-0.8%-1.6%-8.1%-10.0%
3 Year-96.7%-96.7%50.7%46.6%17.3%9.6%
5 Year-99.4%-99.4%81.9%63.2%36.1%21.1%

Price Volatility Vs. Market

How volatile is Aethlon Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Aethlon Medical undervalued compared to its fair value and its price relative to the market?

1.57x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AEMD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AEMD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AEMD is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: AEMD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AEMD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AEMD is good value based on its PB Ratio (1.6x) compared to the US Medical Equipment industry average (2.9x).


Next Steps

Future Growth

How is Aethlon Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

10.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AEMD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AEMD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AEMD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AEMD's revenue is expected to decline over the next 3 years (-22.2% per year).

High Growth Revenue: AEMD's revenue is forecast to decline over the next 3 years (-22.2% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AEMD's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Aethlon Medical performed over the past 5 years?

2.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AEMD is currently unprofitable.

Growing Profit Margin: AEMD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AEMD is unprofitable, but has reduced losses over the past 5 years at a rate of 2.7% per year.

Accelerating Growth: Unable to compare AEMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AEMD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1%).


Return on Equity

High ROE: AEMD has a negative Return on Equity (-164.05%), as it is currently unprofitable.


Next Steps

Financial Health

How is Aethlon Medical's financial position?


Financial Position Analysis

Short Term Liabilities: AEMD's short term assets ($4.3M) exceed its short term liabilities ($810.6K).

Long Term Liabilities: AEMD's short term assets ($4.3M) exceed its long term liabilities ($67.7K).


Debt to Equity History and Analysis

Debt Level: AEMD is debt free.

Reducing Debt: AEMD has no debt compared to 5 years ago when its debt to equity ratio was 22.2%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AEMD has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AEMD has less than a year of cash runway if free cash flow continues to reduce at historical rates of -4.8% each year


Next Steps

Dividend

What is Aethlon Medical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AEMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AEMD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AEMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AEMD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AEMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.5yrs

Average management tenure


CEO

Timothy Rodell (68yo)

1.33s

Tenure

US$1,000,132

Compensation

Dr. Timothy C. Rodell, Jr., M.D., FCCP has been Chief Executive Officer of Aethlon Medical, Inc. since February 14, 2020 and its Director since December 10, 2018. He served as Interim Chief Executive Offic ...


CEO Compensation Analysis

Compensation vs Market: Timothy's total compensation ($USD1.00M) is above average for companies of similar size in the US market ($USD622.20K).

Compensation vs Earnings: Insufficient data to compare Timothy's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Timothy Rodell
CEO & Director1.33yrsUS$1.00m0.098% $11.9k
James Frakes
CFO, Senior VP of Finance & Secretary9.58yrsUS$285.83k0.027% $3.2k
James Joyce
Consultant1.33yrsUS$393.25k0.24% $29.4k
Sunil Sawhney
Head of Clinical Studies15.08yrsno datano data
Richard Tullis
Consultantno datano datano data

5.5yrs

Average Tenure

65yo

Average Age

Experienced Management: AEMD's management team is seasoned and experienced (5.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Timothy Rodell
CEO & Director1.33yrsUS$1.00m0.098% $11.9k
Edward Broenniman
Independent Director21.08yrsUS$79.00k0.070% $8.4k
Nathan Levin
Member of Extracorporeal Therapy Advisory Boardno datano datano data
Gregory T. Kovacs
Member of Extracorporeal Therapy Advisory Boardno datano datano data
Claudio Ronco
Member of Extracorporeal Therapy Advisory Boardno datano datano data
Larry Cowgill
Member of Sepsis & Inflammation Advisory Boardno datano datano data
Charles Fisher
Independent Chairman & Member of Extracorporeal Therapy Advisory Board2.42yrsUS$159.00k0.046% $5.6k
John Kellum
Member of Extracorporeal Therapy Advisory Boardno datano datano data
Chetan Shah
Independent Director6.83yrsUS$78.00k0.25% $30.2k
David Ward
Member of Extracorporeal Therapy Advisory Boardno datano datano data

4.6yrs

Average Tenure

70yo

Average Age

Experienced Board: AEMD's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.9%.


Top Shareholders

Company Information

Aethlon Medical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aethlon Medical, Inc.
  • Ticker: AEMD
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$12.081m
  • Shares outstanding: 9.36m
  • Website: https://www.aethlonmedical.com

Number of Employees


Location

  • Aethlon Medical, Inc.
  • 9365 Granite Ridge Drive
  • Suite 100
  • San Diego
  • California
  • 92123
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AEMDNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMar 1999
EJUBST (Boerse-Stuttgart)YesCommon StockDEEURMar 1999
EJUDB (Deutsche Boerse AG)YesCommon StockDEEURMar 1999

Biography

Aethlon Medical, Inc., a medical technology company, focuses on addressing unmet needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. The company is based in San Diego, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/08 03:46
End of Day Share Price2020/04/07 00:00
Earnings2019/12/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.